Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cogent Biosciences webcast. (Operator Instructions) Please note that this conference is being recorded.
I will now hand the conference over to your speaker host for today, Christi Waarich, Senior Director of Investor Relations. Please go ahead.
Thank you, operator. Today's call will review the positive lead-in data from our ongoing Phase III PEAK trial, evaluating bezuclastinib and sunitinib in patients with GIST. These data were presented in the poster session at ASCO and released in a press release over the weekend. You can find the press release in the Investors & Media section of our website at cogentbio.com.
Before we get started, please be reminded that remarks made during this call may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development time lines,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |